Development of a Multifaceted Program for Pharmacogenetics Adoption at an Academic Medical Center: Practical Considerations and Lessons Learned
Open Access
- 21 August 2024
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 116 (4) , 914-931
Abstract
In 2019, Indiana University launched the Precision Health Initiative to enhance the institutional adoption of precision medicine, including pharmacogenetics (PGx) implementation, at university‐affiliated practice sites across Indiana. The overarching goal of this PGx implementation program was to facilitate the sustainable adoption of genotype‐guided prescribing into routine clinical care. To accomplish this goal, we pursued the following specific objectives: (i) to integrate PGx testing into existing healthcare system processes; (ii) to implement drug–gene pairs with high‐level evidence and educate providers and pharmacists on established clinical management recommendations; (iii) to engage key stakeholders, including patients to optimize the return of results for PGx testing; (iv) to reduce health disparities through the targeted inclusion of underrepresented populations; (v) and to track third‐party reimbursement. This tutorial details our multifaceted PGx implementation program, including descriptions of our interventions, the critical challenges faced, and the major program successes. By describing our experience, we aim to assist other clinical teams in achieving sustainable PGx implementation in their health systems.Keywords
Funding Information
- Indiana University
- National Institute of General Medical Sciences (K23GM147805, T32GM144891)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08DK107864)
This publication has 108 references indexed in Scilit:
- The State of State Biomarker Testing Insurance Coverage LawsJAMA, 2024
- Impact of the CYP2C19*17 Allele on Outcomes in Patients Receiving Genotype‐Guided Antiplatelet Therapy After Percutaneous Coronary InterventionClinical Pharmacology & Therapeutics, 2020
- Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary InterventionJAMA, 2020
- Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 UpdateClinical Pharmacology & Therapeutics, 2018
- Electronic Health Record Usability Issues and Potential Contribution to Patient HarmJAMA, 2018
- Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and ProjectsClinical Pharmacology & Therapeutics, 2018
- Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype‐Guided Antiplatelet TherapyClinical Pharmacology & Therapeutics, 2017
- Association BetweenCYP2C19Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic AttackJAMA, 2016
- Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus DosingClinical Pharmacology & Therapeutics, 2015
- Implementation of pharmacogenetics: The University of Maryland personalized anti‐platelet pharmacogenetics programAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2014